BB Biotech — Lower rates and news flow to support recovery

Investment Companies

BB Biotech

Lower rates and news flow to support recovery

Investment companies
Biotechnology equities

14 August 2024

Price		CHF39.75
Market cap		CHF2,202.2m
AUM		CHF2,368.4m

NAV*		CHF42.75
Discount to NAV		7.0%
*Including income. At 13 August 2024.
Yield		5.0%
Ordinary shares in issue		55.4m
Code/ISIN		BION/CH0038389992
Primary exchange		SIX
AIC sector	N/A
52-week high/low	CHF49.35		CHF35.60
NAV* high/low	CHF56.00		CHF36.00
*Including income
Gearing (at 30 June 2024)				13.5%
Fund objective BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION’s benchmark is the Nasdaq Biotechnology Index (in Swiss francs) but it is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.
Bull points
■ Bellevue Asset Management has 30 years’ experience in the sector, with proven expertise in backing innovative companies, such as Moderna (bought pre-IPO). ■ The prospect of lower interest rates bodes very well for the small-cap biotech sector. ■ BION makes unique use of AI and big data to support the investment decision-making process.
Bear points
■ Biotech stocks can be volatile, as the development process for new drugs and therapies is very uncertain and some will fail or otherwise disappoint expectations. ■ Gearing increases exposure to downside risks. ■ BION invests in foreign currencies, which brings a corresponding degree of currency risk versus the reference currency.

Analyst

Joanne Collins

+44 (0)20 3077 5700

investmenttrusts@edisongroup.com

Edison profile page

BB Biotech is a research client of Edison Investment Research Limited

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. The company recently released its interim report for the period ended 30 June 2024, which provided an update on recent performance and developments with portfolio companies, and outlined the major milestones expected from these holdings during the second half of 2024. This note summarises the key points from the report, and the reasons why BION’s managers are optimistic about the outlook for the biotech sector and for their portfolio.

BION’s performance relative to the Nasdaq Biotech Index (CHF) over 10 years

Source: LSEG Data & Analytics, Edison Investment Research. Note: Total returns in Swiss francs.

The analyst’s view

■

BION delivered a significant outright gain of 19.9% in NAV terms over the year ended 31 July 2024, very close to the benchmark return of 20.1%, and its longer-term performance remains robust in absolute and relative terms. In the 10 years to 31 July 2024, BION made an average annual return of 6.9% in NAV terms, above the benchmark return of 6.6%.

■

The managers expect lower interest rates and a series of key milestones to support portfolio holdings over H224 and beyond. Their optimism about the company’s prospects is reflected in the fact that gearing stood at 13.5% at end June 2024, at the upper limit of its target range.

■

BION’s shares have traded at an average premium to NAV of around 10% over the past 10 years. However, the share price drifted into discount territory last year and the shares are currently trading at a discount of around 10%. With long-term performance ahead of benchmark and the sector outlook potentially brightening, this may represent an opportunity for investors to acquire access to this vibrant industry at what may be an uncommonly wide discount.

■

BION’s interim report included news of a leadership change in the investment management team. The team’s long-serving head, Dr Daniel Koller, has announced his retirement effective end 2024. He will be replaced by Dr Christian Koch, one of the company’s two deputy heads, who has been a portfolio manager at Bellevue Asset Management since 2014. Investors are likely to be reassured by this orderly transition, and the continuity of management it represents.

BION: More positive news expected in H224

Annual returns, at 19.9%, are close to the benchmark

After a strong start to 2024, the biotech sector consolidated in the second quarter, lagging global equity markets, which extended the strong rally that began in late 2023. Small-cap biotech companies in the under US$1bn market cap space experienced some correction in their share prices during Q224, and M&A activity in the sector, which often contributes to performance, was muted.

Against this subdued backdrop, BB Biotech’s recent performance has been mixed. In the six months ended 31 July 2024, the company returned 8.6% (in CHF in NAV terms), behind the 13.9% return of its benchmark, the Nasdaq Biotechnology Index (NBI). BION’s share price declined 2.1%. However, over the year to end July 2024, performance was stronger in absolute terms (+19.9% in NAV terms), and very close to the benchmark return of 20.1%, although BION’s share price dropped 3.1% over the period, widening the discount at which the company’s share price trades relative to its NAV. Its longer-term performance remains robust in absolute and relative terms. In the 10 years to end July 2024, BION made an average annual return of 6.9% in NAV terms and 8.0% on a share price basis, slightly above the benchmark return of 6.6%.

Exhibit 1: Five-year discrete performance data

12 months ending	Share price (%)	NAV (%)	Nasdaq Biotech CHF (%)	MSCI World Health Care CHF (%)	CBOE UK All Cos CHF (%)	MSCI World CHF (%)
31/07/20	7.6	11.2	17.6	10.7	(19.7)	(0.9)
31/07/21	37.7	25.2	21.9	22.7	33.4	35.2
31/07/22	(30.6)	(27.5)	(19.5)	2.7	(2.4)	(4.1)
31/07/23	(16.7)	(8.3)	(2.9)	(4.6)	2.4	3.8
31/07/24	(3.1)	19.9	20.1	15.7	14.9	20.7

Source: LSEG Data & Analytics, Bloomberg. Note: All % on a total return basis in Swiss francs.

Exhibit 2: Investment company performance to 31 July 2024
Price, NAV and benchmark total return performance, 10 years rebased	Price, NAV and benchmark total return performance (%)

Source: LSEG Data & Analytics, Bloomberg, Edison Investment Research. Note: Three-, five- and 10-year performance figures annualised.

Recent milestones have had a mixed impact on returns

BION’s managers believe that many of the company’s portfolio holdings have strengthened their financial positions and de-risked their growth trajectories over recent months. They cite developments related to three of BION’s largest holdings, Alnylam Pharmaceuticals, Intra-Cellular Therapies and Agios Pharmaceuticals, which all saw substantial improvements in their medium- to long-term revenue and growth prospects following positive Phase III readouts. The most significant of these was Alnylam’s positive clinical trial result for vutrisiran, which we covered in a flash note in June 2024. BION’s managers believe that the multi-billion-dollar revenue opportunity for vutrisiran to treat cardio TTR patients places Alnylam on the path to become a large, high-growth, profitable biotech company. The stock has risen by over 50% since the results were publicised.

Other significant positive developments among portfolio holdings included:

■

The announcement by Agios that the Phase III ENERGIZE-T clinical study of mitapivat met the primary endpoint and all key secondary endpoints in adults with transfusion dependent alpha- or beta-thalassemia. Agios plans a regulatory submission by the end of 2024, for all forms of thalassemia, with potential approval in 2025. Importantly, Agios expects the Phase III mitapivat trial for sickle cell patients to read out in 2025.

■

A report from Intra-Cellular Therapies of positive topline results in the second Phase III trial evaluating lumateperone as an adjunctive therapy in patients with major depressive disorder (MDD). The company intends to file a supplemental New Drug Application (NDA) for the adjunct treatment of MDD in H224. If approved in 2025, Caplyta (lumateperone) would be accessible to MDD patients, a much larger market opportunity than the already approved treatment indications for patients with schizophrenia and bipolar disorder.

■

News from Annexon Biosciences, a new position initiated in Q124, that a single infusion of ANX005 resulted in a significant improvement on the Guillain-Barré syndrome disability scale. Following the positive update, the company strengthened its balance sheet with a US$125m public offering, although BION did not participate.

The second quarter also saw one product approval and a notable product label addition for BION investments. Moderna gained US Food and Drug Administration (FDA) approval and a recommendation from the Centers for Disease Control and Prevention (CDC) of its RSV vaccine mRESVIA, while Argenx’s VYVGART Hytrulo, the subcutaneously administered version of Vyvgart, was approved by the FDA to treat patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

BION’s returns were also bolstered to a modest extent by the devaluation of the Swiss franc against the US dollar in H124.

However, several of the company’s other small-cap holdings have detracted from performance in Q224. The most significant detractor from performance over recent months was MacroGenics, following a disappointing update for the TAMARACK study of vobra duo in prostate cancer patients. The stock subsequently lost two-thirds of its value, resulting in a 4% decline in BION’s NAV. Further safety and efficacy data are due in H224 and updates on a next-generation drug delivery program against the same target are expected in 2025. BION still holds this name in anticipation of more promising developments.

In addition:

■

Sage Therapeutics’s SAGE-718 failed to improve cognitive impairment in Parkinson’s disease patients versus placebo in a Phase II trial. Further Phase II trials testing SAGE-718 in patients with Alzheimer’s disease and Huntington’s disease will report in H224.

■

Immunocore disappointed market expectations on the objective response rate (ORR) of Tebentafusp and the company’s valuation dropped in response to early data on its Phase I trial of brenetafusp (IMC-F106C) for patients with cutaneous melanoma.

Portfolio activity: Profit-taking, top-ups and one new name

Since our May 2024 review, BION’s main portfolio changes have involved capitalising on gains from several larger, established long-term holdings. The team took some profits on Vertex Pharmaceuticals, Argenx, Intra-Cellular Therapies, Moderna, Neurocrine Biosciences and Agios Pharmaceuticals. They also added to existing positions in several newer holdings, including Annexon Biosciences, a Q124 acquisition, and Biohaven and Immunocore, both purchased in Q423. The team also topped up a position in Celldex Therapeutics, following pipeline progress and an improvement in its balance sheet, and made one new acquisition: Edgewise Therapeutics, which focuses on developing therapeutic candidates aimed at regulating key muscle proteins, for both skeletal and cardiac muscles.

Several reasons for the managers’ confidence in the outlook

Looking ahead, BION’s managers expect several key factors to play a significant role in shaping the biotech landscape and the company’s performance. Key among these is the trajectory of interest rates, as the long-term nature of biotech investments makes their valuations especially sensitive to interest rate moves. Once US interest rates begin to track lower, biotech stock valuations are expected to benefit, and the sector is likely to attract new capital inflows.

After a slow start to the year, BION’s managers are expecting a pick-up in M&A activity in H224 and beyond. This will be driven in part by the expiry of several drug patents in coming years, which will allow generic versions of these drugs to be sold by competitors at potentially much lower prices. Large pharmaceutical companies will therefore need to seek replacement income from new patented products, including via strategic acquisitions of smaller, attractively priced biotech companies with innovative technologies and promising pipelines. Many, if not all, of BION’s portfolio holdings are potential targets for such activity.

In terms of forthcoming key milestones for BION’s portfolio holdings, in addition to the MacroGenics update mentioned above, updates are due from:

■

Arvinas, which is due to present pivotal top-line Phase III data from the Veritac-2 clinical study, testing vepdegestrant as monotherapy in second-line ER+/HER2- breast cancer patients;

■

Scholar Rock and Biohaven, which will announce top-line Phase III results for their TGF-beta antibodies for spinal muscle atrophy patients;

■

Revolution Medicine, which is due to provide further clinical data for RMC-6236, its KRAS multi-inhibitor, as well as its G12D inhibitor, RMC-9805;

■

Black Diamond: initial Phase II results in second- and third-line non-small cell lung cancer patients with EGFR mutations are expected in H224; and

■

Edgewise Therapeutics, BION’s newest acquisition, which is due to report proof-of-concept data for EDG-7500 for hypertrophic cardiomyopathy patients and further data for Sevasemten for Becker and Duchenne patients.

Looking further ahead, Moderna is making a significant investment in a respiratory virus vaccine franchise. Its Phase III data for the combination vaccine against influenza and COVID-19 was positive and the company is developing single injections covering double and triple combinations of influenza, RSV and SARS-CoV2, with double vaccines available in 2025 and the triple vaccine expected in 2026.

Product approvals expected in H224 include:

■

Crinecerfont, from Neurocrine Biosciences, in congenital adrenal hyperplasia patients of all ages;

■

Olezarsen, from Ionis Pharmaceuticals, as treatment for familial chylomicronemia syndrome patients; and

■

Axatilimab, from Incyte and Syndax Pharmaceuticals, for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.

On the political front, the outcome of November’s US presidential election may have important implications for the healthcare sector, especially drug pricing, so investors will be monitoring developments closely.

However, overall, the managers are positive on the outlook for the sector, and their portfolio, thanks to the combination of ‘strengthening fundamentals, anticipated clinical milestones and supportive capital market dynamics’. Their confidence is manifest in the current level of portfolio gearing, which stood at 13.5% at end-Q124. This is at the high end of the company’s defined range.

Dr Christian Koch to assume lead manager role in 2025

The other important recent news from BION is that its lead portfolio manager, Dr Daniel Koller, has informed the board of his intention to retire at the end of 2024, after 20 years in the company’s investment management team, including 14 years as its head. Dr Christian Koch, one of the two deputy heads of the investment management team and a portfolio manager at Bellevue Asset Management since 2014, will take over from Dr Koller as head of the team at the beginning of 2025. Before joining Bellevue, Dr Koch was a sell-side pharma and biotech equity analyst at Bank am Bellevue in Küsnacht and spent three years as a research associate at the Institute of Pharmaceutical Sciences at the ETH Zurich. He holds a PhD in computer-assisted drug design from the ETH Zurich and studied bioinformatics at the Goethe University Frankfurt.

For more Edison research on the life sciences sector, please see Outlook for 2024: Life sciences – Where has the conviction gone?

General disclaimer and copyright

This report has been commissioned by BB Biotech and prepared and issued by Edison, in consideration of a fee payable by BB Biotech. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

Australia

New Zealand

United Kingdom

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

Equities

Equities by Sector

Sectors

Thematics

Latest

Vietnam Holding – Vietnam in the global digital race

US small-cap equities – Time to shine?

MediaWatch – Encouragements and frustrations

Audiovisual

Latest

BlackRock Latin American Investment Trust in 60 seconds

Uncovering Trusts – The Law Debenture Corporation (LWDB)

Edinburgh Worldwide Investment Trust – executive interview

About Edison

About Edison

Careers

BB Biotech (BION)

BB Biotech — Lower rates and news flow to support recovery

Investment Companies

Investment Companies

Latest

Basilea Pharmaceutica — Poised for an eventful H224

Immix Biopharma — Full steam ahead with US CAR-T trial

Deutsche Beteiligungs — Doubling down on investment opportunities

Pan American Silver — Q224 results: Steady progress

Sylvania Platinum — Long-term PGM price upside

More on BB Biotech